Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioCardiaSTU:6JU0 21 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates STU:6JU0 with a GF Score™ of 21/100. The stock has 1 warning sign investors should review. Among 702 Biotechnology companies, BioCardia ranks worse than 142450% on this metric.
The historical rank and industry rank for BioCardia's Days Payable or its related term are showing as below:
During the past 13 years, BioCardia's highest Days Payable was 75737.50. The lowest was 256.87. And the median was 580.68.
STU:6JU0's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.1 * Ranked among companies with meaningful Days Payable only.
BioCardia's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
BioCardia Days Payable Related Terms
BioCardia Days Payable Historical Data
* Premium members only.
The historical data trend for BioCardia's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:6JU0 vs GRTX, CELU, KTTA: Days Payable Comparison
For the Biotechnology subindustry, BioCardia's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioCardia Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioCardia's Days Payable distribution charts can be found below:
* The bar in red indicates where BioCardia's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
BioCardia's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioCardia (STU:6JU0) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioCardia and its competitors. Over the past decade, BioCardia's Days Payable has ranged from 256.87 to 75,737.50. According to the industry distribution chart, BioCardia ranks #999999 out of 702 companies in the Biotechnology industry.
Is BioCardia's Days Payable too high?
BioCardia's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 256.87 to a high of 75,737.50. Based on the distribution chart, BioCardia ranks #999999 out of 702 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioCardia has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does BioCardia's Days Payable compare to GRTX and CELU?
According to the Biotechnology industry distribution chart, BioCardia ranks #999999 out of 702 companies for Days Payable. This places BioCardia in the lower half of its industry. The industry median Days Payable is 113.10. Historically, BioCardia's own Days Payable has ranged from 256.87 to 75,737.50 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioCardia and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioCardia's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCardia stock overvalued right now?
BioCardia (STU:6JU0) has a current Days Payable of 0.00. The current Days Payable is 0.00. BioCardia's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For BioCardia (STU:6JU0), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
21GF Score
Get the complete analysis for STU:6JU0
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6JU0 has been successfully added to your 
